RecruitingNCT00919217
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Exploratory Study on the Timing of MS Symptoms
Sponsor
University of Louisville
Enrollment
80 participants
Start Date
Aug 1, 2008
Study Type
OBSERVATIONAL
Conditions
Summary
The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years
Plain Language Summary
Simplified for easier understanding
This study is researching whether the timing and nature of multiple sclerosis (MS) symptoms are related to hormonal and immune changes throughout the menstrual cycle in women with relapsing-remitting MS.
**You may be eligible if...**
- You are a woman
- You have been diagnosed with relapsing-remitting multiple sclerosis (the most common type of MS)
**You may NOT be eligible if...**
- You are male
- You do not have a relapsing-remitting MS diagnosis
- You have another autoimmune disease or fibromyalgia
- You are menopausal or post-menopausal (naturally or surgically)
- You have been pregnant in the past year or are currently breastfeeding
- You have a history of chemotherapy
- You are on experimental medications
- You have used steroids in the last 30 days
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00919217
Related Trials
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT067965045 locations
Functional Outcomes From Diets in Multiple Sclerosis
NCT053273222 locations
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
NCT059495805 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT0404762822 locations
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
NCT037834161 location